Circulating tumor cell data: Integration with imaging and serum tumor markers for metastatic breast cancer patient management

Case Reports in Oncology

Volumn 7, Issue 1, 2014, Pages 175-181

  Marsland, Thomas ^a   Schuur, Eric R ^b,c  

^a Integrated Community Oncology Network   (United States)

^b VMWA LLC   (United States)

^c The Jon Block Group   (United States)

Author keywords

Breast cancer; Circulating tumor cells; Decision making

Indexed keywords

BEVACIZUMAB; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DOXORUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; LETROZOLE; PACLITAXEL; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; TUMOR MARKER; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CAUCASIAN; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FEMUR TUMOR; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LOW BACK PAIN; MIDDLE AGED; NEUROPATHY; PARTIAL MASTECTOMY; PATIENT CARE; PRIORITY JOURNAL; TREATMENT REFUSAL;

EID: 84900493687     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000360983     Document Type: Article

References (15)

1. SEER cancer statistics review 1975-2009 (vintage 2009 populations). 2012. http://seer.cancer.gov/csr/1975-2009-pops09/(accessed September 11, 2012).
2. Alemar J, Schuur ER: Progress in using circulating tumor cell information to improve metastatic breast cancer therapy. J Oncol 2013;2013:702732.
3. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-3221.
4. Cristofanilli M, Budd, GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med 2004;351:781-791.
5. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058.
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH: Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-1563.
7. Poveda A, Kaye, SB, Mccormack R, Wang S, Parekh T, Ricci D, Lebedinsky CA, Tercero JC, Zintl P, Monk BJ: Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 2011;122:567-572.
8. Sergeant G, Van Eijsden R, Roskams T, Van Duppen V, Topal B: Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer 2012;12:527.
9. Hayes DF, Smerage J: Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res 2008;14:3646-3650.
10. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
11. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409.
12. Beveridge R: Circulating tumor cells in the management of metastatic breast cancer patients. Community Oncol 2007;4:79-82.
13. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904.
14. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-1795.
15. Schnipper LE, Lyman GH, Blayney DW, Hoverman JR, Raghavan D, Wollins DS, Schilsky RL: American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 2013;31:4362-4370.